


Some infants are ahead of their time.




Fortunately, so are we.

Cow & Gate has been looking after the nutritional needs of infants for over 90 years. During that time, we've created the widest range of formulas and foods for normal infants and those with very special needs.

The low birth weight baby is one of them.

Our Low Birth Weight Formula was specially created to provide higher energy and nutrient levels, at a lower volume than might otherwise be obtained from breastmilk or standard infant formula – an important consideration in the prevention of problems associated with immature digestive systems.



This formulation was one of the first designed to meet the guidelines set out by ESPGAN, the European Society of Paediatric Gastroenterology and Nutrition.

And it still offers the lowest osmolality and lowest renal solute load of any low birth weight formula available today.

Cow & Gate Low Birth Weight Formula. Well-absorbed. Proven well-tolerated.

And just one of an ever increasing range of infant formulas and foods from a specialist ahead of its time.

Extra nourishment when it's needed most

**Cow
& Gate**

Convenient 60ml size
means less waste

VENTODISKS

(Salbutamol BP)

Making sure Ventolin gets through



Ventodisks (Salbutamol BP)

Abridged Prescribing Information: (Please refer to full data sheet before prescribing.)

Uses: Treatment and prophylaxis of acute and chronic bronchospasm.

Dosage and administration: *Adults:* Ventodisks – 400 micrograms, as a single dose or three to four times daily. *Children:* Ventodisks – 200 micrograms, up to four times daily.

Contra-indications: Threatened abortion during first or second trimester. Hypersensitivity.

Precautions: If previously effective dose lasts less than three hours, seek medical advice. Caution in patients with thyrotoxicosis. Avoid use with non-selective beta-blockers.

Pregnancy: Avoid unnecessary use during early pregnancy.

Side-effects: Mild tremor, headache occur rarely. Very rarely – transient muscle cramps and hypersensitivity reactions. Paradoxical bronchospasm could occur – substitute alternative therapy.

Presentation and Basic NHS cost: Ventodisks – pack of 14 Ventodisks each containing 8 x 200 micrograms Salbutamol BP (as sulphate) – light blue or 8 x 400 micrograms Salbutamol BP (as sulphate) – dark blue, together with a Ventolin Diskhaler. For inhalation. £7.11 and £12.02. Refill pack of 14 x 8 Ventodisks 200 micrograms or 14 x 8 Ventodisks 400 micrograms £6.54 and £11.45.

Product licence numbers: Ventodisks 200 micrograms 0045/0134, Ventodisks 400 micrograms 0045/0135.



ALLEN & HANBURY'S

Full prescribing information is available on request from: Allen & Hanburys Limited
Greenford, Middlesex UB6 0HE


Ventodisks should only be used with a Ventolin Diskhaler. Ventodisks and Ventolin are trade marks

Ventodisks is a dependable breath-operated system delivering Ventolin to the lungs without the need for synchronisation.

Furthermore, the disks provide a simple visual check on the number of doses delivered – an advantage for both children and adults.

VENTODISKS

(Salbutamol BP)



WHAT'S A FEW INCHES BETWEEN FRIENDS?



For the girl with
Turner Syndrome
it can mean
getting the most
out of childhood.

Genotropin is
now indicated for
the treatment of
short stature in
Turner Syndrome.

The earlier
Genotropin
treatment is started
the greater is the
effect on growth.*

*See Genotropin Summary of Product Characteristics for details.
© Kabi Vitrum Ltd. 1990

GenotropinTM


somatropin (rbe)



ABBREVIATED PRESCRIBING INFORMATION **Presentation** *Genotropin 12IU Multidose* A vial of sterile lyophilised powder containing 12 IU somatropin (rbe) supplied with 3 ml of Water for Injections with 0.25% m-cresol for reconstitution. *Genotropin 4IU* A vial of sterile lyophilised powder containing 4 IU somatropin (rbe) supplied with 1 ml of Water for Injections. **Indications** The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. The diagnosis should be verified by a specialist medical practitioner. Short stature in gonadal dysgenesis (Turner Syndrome). **Reconstitution** Add 3 ml of Water for Injections with 0.25% m-cresol to the 12 IU and 1 ml Water for Injections to the 4 IU in the vial. Dissolve the drug gently without shaking vigorously. **Dosage and Administration** Administer by subcutaneous injection. Generally a dose of 0.5 - 0.7 IU/kg body weight per week is recommended divided into six or seven subcutaneous injections. In Turner Syndrome a dose of 1.0 IU/kg body weight per week is recommended. **Contra-Indications** Only patients with unfused epiphyses should be treated. **Precautions** Patients with diabetes mellitus may require adjustment of their antidiabetic therapy. Patients treated with Genotropin should be regularly assessed by a child growth specialist. The injection site should be rotated to prevent lipatrophy. **Pregnancy and Lactation** In the event of pregnancy occurring during Genotropin therapy, treatment should be discontinued. No information is available as to whether peptide hormones pass into breast milk. **Side-Effects** A few children have developed transient local reactions. In Turner Syndrome temporary exacerbation of lymphoedema has been reported. Antibodies towards growth hormone may be formed in some patients but these antibodies rarely have clinical significance. **Pharmaceutical Precautions** Store between 2-8°C and protect from light. Reconstituted Genotropin 12 IU Multidose may be used over a period of 21 days if kept in the refrigerator. Genotropin 4 IU is for single use only. **Legal Category** POM. **Package Quantities** *Genotropin 12 IU Multidose* Combined pack containing one vial of somatropin (rbe) 12 IU and one ampoule of 3 ml Water for Injections with 0.25% m-cresol. *Genotropin 4 IU* Two pack sizes of Genotropin 4 IU are available: a combined pack containing one vial of somatropin (rbe) 4 IU and one ampoule of 1 ml Water for Injections; and a combined pack containing ten vials of somatropin (rbe) 4 IU and ten ampoules of 1 ml Water for Injections. **Product Licence Numbers** Genotropin 12 IU Multidose PL 0022/0079. Water for Injections with 0.25% m-cresol PL 0022/0081. Genotropin 4 IU PL 0022/0071. Water for Injections PL 0022/0082. **Price NHS Prices:** 12 IU Multidose £91.50 4 IU £30.50 10 x 4 IU £305.00. **Product Licence Holder** KabiVitrum Ltd, Dukes Meadow, Millboard Road, Bourne End, Bucks SL8 5XF. Further information is available on request from the Product Licence Holder. **SPECIAL REPORTING TO CSM REQUIRED**


KABI

Specially for kids



MR STRONG

MR CLEVER



MR GREEDY



MR HAPPY



LITTLE MISS HELPFUL

Fortison® Paediatric has been specifically formulated for young children requiring a nasogastric tube feed. It is a balanced, sterile feed, based on the 1988 BDA Paediatric and PEN Group Joint Working Party guidelines.¹

Furthermore, Fortison® Paediatric is ready-to-use

and has the advantages of saving time, and reducing inaccuracy of nutrient levels and contamination risks, compared with modified adult formulas.

To help patients and ward staff with feeding time, Cow & Gate will be providing a range of MR MEN educational and fun items.

Fortison® paediatric

**ready-to-use
nasogastric feed**

1. Paediatric Enteral Feeding Solutions and Systems. A Report by the Joint Working Party of the Paediatric Group and the Parenteral and Enteral Nutrition Group of the British Dietetic Association, 1988.


Cow & Gate CLINICAL CARE

Leaders in scientific nutrition Cow & Gate House, Trowbridge, Wiltshire BA14 8YX. Tel: 0225 768381

Fortison is a trademark

CC421/5/90

A breakthrough in seizure control...



..in uncontrolled epilepsy
a >50% reduction in seizure
frequency in approximately
50% of patients⁽¹⁾

- No therapeutically significant drug interactions with other anti-convulsants^{(2-5)*}
- Flexible dosing - once or twice daily



SABRIL
VIGABATRIN

Specific GABA-transaminase inhibition
for uncontrolled epilepsy

*Decreases of about 20% in plasma phenytoin levels have been reported but these are unlikely to be of therapeutic significance.

Merrell Dow Pharmaceuticals Limited, Lakeside House, Stockley Park, Uxbridge, Middlesex UB11 1BE
TRADEMARKS Sabril, Merrell Dow.

**MERRELL
DOW**

Sabril Abridged Prescribing Information ▼


Presentation White, oval biconvex tablets with a breakline on one side and SABRIL on the other. Each tablet contains 500 mg vigabatrin. **Uses** *Mode of Action* A selective, irreversible inhibitor of GABA-transaminase. Treatment leads to an increase in brain levels of GABA (gamma aminobutyric acid). **Indications** Indicated for the treatment of epilepsy which is not satisfactorily controlled by other antiepileptic drugs. **Dosage and Administration** For oral administration once or twice daily and may be taken before or after meals. **Adults:** The recommended daily starting dose is 2 g (4 tablets) which should be added to the patient's current therapeutic regimen. The dose may be increased or decreased in 0.5 g or 1.0 g increments depending upon clinical response and tolerability. Increasing the dose above 4 g/day does not usually result in improved efficacy. There is no direct correlation between plasma concentration and efficacy. The duration of the effects of the drug are dependent on the rate of enzyme resynthesis rather than the concentration of drug in the plasma. **Children:** The recommended daily starting dose is 1 g (2 tablets) in children aged 3-9 years and 2 g (4 tablets) in older children. **Elderly:** Dosage reduction may be necessary in patients with impaired renal function, particularly patients with creatinine clearance less than 60 ml/min. See "Precautions." **Contra-indications, Precautions, Warnings etc.** *Use in pregnancy and lactation:* Use of Sabril during pregnancy is contra-indicated. There is no evidence of the safety of Sabril treatment whilst breast-feeding and so it is not recommended. **Precautions:** As with other antiepileptic drugs abrupt withdrawal may lead to rebound seizures. If treatment is to be discontinued it is recommended that this is done by gradually reducing the dose over 2-4 weeks. Sabril should be used with caution in patients with a history of psychosis or behavioural problems (see under side-effects). Caution should be exercised when administering the product to elderly patients and more particularly patients with creatinine clearance of less than 60 ml/min. Reduced doses should be used and patients monitored closely for adverse events such as sedation and confusion. **Warnings:** Animal safety studies indicate that vigabatrin causes intramyelinic oedema in the brain white matter tracts. Currently there is no evidence to suggest that this effect occurs in man. However, it is recommended that patients treated with Sabril are closely observed for adverse effects on neurological function. Details of animal findings are given under "Further Information" in the full product data sheet. **Effects on driving ability:** Drowsiness has been observed and patients should be warned of this possibility before treatment. Special care should be taken by patients driving, operating machinery or performing any hazardous task. **Side-effects:** Adverse events are mainly CNS related and probably a secondary consequence of the increase in GABA caused by Sabril. Aggression and psychosis have been reported and a previous history of psychosis or a behavioural problem appears to be a predisposing factor to such reactions. Other events reported are: drowsiness and fatigue, dizziness, nervousness, irritability, depression, headache, weight gain, gastro-intestinal side-effects and less commonly confusion, memory disturbance and vision complaints such as diplopia. In children excitation and agitation have been seen. The sedative effect of vigabatrin decreases with continuing treatment. As with other antiepileptic drugs, some patients may experience an increase in seizure frequency with vigabatrin. Patients with myoclonic seizures may be particularly liable to this effect. There is no evidence of neurotoxicity in humans. Tests done to confirm lack of significant adverse effect on neurological function include evoked potentials, CAT scans, magnetic resonance imaging, CSF analyses and in a small number of cases, neuropathological examinations of brain specimens. Laboratory data indicate that Sabril treatment does not lead to renal or hepatic toxicity. Decreases in SGOT and SGPT have been observed and may be a result of inhibition of these transaminases by Sabril. Chronic treatment with Sabril may be associated with a slight decrease in haemoglobin which rarely attains clinical significance. **Drug Interactions:** Sabril is not metabolised, or protein bound and does not induce hepatic cytochrome P450 or drug metabolising enzymes so interactions with other drugs are unlikely. In clinical studies a gradual reduction of about 20% in plasma phenytoin concentration has been observed. The mechanism is not understood but this is unlikely to be of therapeutic significance. No clinically significant interactions have been seen with carbamazepine, phenobarbitone or sodium valproate in clinical trials. **Overdose:** There is no specific antidote and the usual supportive measures should be employed. Overdoses of 14 and 30 g of Sabril have been reported without any sequelae. **Pharmaceutical Precautions** None. **Legal Category** POM. **Package Quantities** Blister strips of 10 in cartons of 100. **Product Licence Number:** PL 4425/0098. **NHS Price:** pack of 100 tabs. £46.00. **Date of Preparation:** July 1990. **You must refer to the full prescribing information before administering Sabril.** Further information including full product data sheet is available from the Licence Holder: Merrell Dow Pharmaceuticals Ltd., Lakeside House, Stockley Park, Uxbridge, Middx UB11 1BE.

References

1. Mumford JP. Br J Clin Pract 1988; 42 (Suppl 61): 7-9.
2. Browne TR, et al. Neurology 1987; 37: 184-189.
3. Tartara A, et al. Epilepsia 1986; 27: 717-723.
4. Tassinari CA, et al. Arch Neurol 1987; 44: 907-910.
5. Rimmer EM, Richens A. Lancet 1984; 1: 189-190.

Trademarks: Sabril, Merrell Dow.

**MERRELL
DOW**



Just published

As a health professional, you may find that children from ethnic minorities in Britain suffer from conditions that you have never encountered—such as diseases of genetic or nutritional origin and tropical or subtropical infestations. They, or their parents, may not speak enough English to be able to explain what is wrong and, in addition, cultural differences may impede understanding on both sides. What can be done? In *Child Health in a Multicultural Society* Dr John Black gives a brief introduction to the problems of ethnic minorities together with a detailed guide to the cultures of particular groups—Asian families, families from the Mediterranean and Aegean, Chinese and Vietnamese families, and Afro-Caribbean and African families—and the diseases to which they may be vulnerable. This new revised edition (previously entitled *The New Paediatrics*) is a valuable guide for doctors, nurses, and non-medical staff who want to ensure the best care for all patients.


Price: Inland £5.95; Abroad £7.00
BMA members: Inland £5.45; Abroad £6.50
including postage, by air abroad

Order from: BRITISH MEDICAL JOURNAL, PO BOX 295, LONDON WC1H 9TE or any leading bookseller.
Please enclose payment with order, or send us full details of your MASTERCARD, VISA or AMERICAN EXPRESS credit card.

RSV POSITIVE?

USE VIRAZID[®] EARLY

Ribavirin



YOU CAN TREAT THE INFECTION NOT JUST THE SYMPTOMS

Prescribing Information ▼

Indications

Virazid is indicated in the treatment of infants and children with severe respiratory syncytial virus bronchiolitis.

Dosage

Treatment is carried out using a small particle aerosol generator (SPAG) for 12-18 hours per day for at least 3 and no more than 7 days. The concentration of ribavirin in the reservoir is 20mg/ml in the SPAG unit and the average concentration for a 7 hour period is 0.19mg/l of air.

Presentation

Virazid is a sterile lyophilised powder of ribavirin to be reconstituted for aerosol administration. Each 100ml glass vial contains 6g of ribavirin and, when reconstituted to the correct volume of 300ml with Water for Injections BP, will

contain 20mg/ml ribavirin at a pH of approximately 5.5.

Contra-Indications

Ribavirin is contra-indicated in females who are or may become pregnant and it should be noted that ribavirin can be detected in human blood even four weeks after oral administration has ceased.

Precautions

In infants requiring assisted ventilation, Virazid should only be used when there is constant monitoring of both patients and equipment.

Side Effects

Several serious adverse events occurred in severely ill infants with life-threatening underlying disease many of whom required

assisted ventilation. These events included worsening of respiratory status, bacterial pneumonia and pneumothorax. The role of ribavirin aerosol in these events has not been determined.

Anaemia has been reported with oral and intravenous administration but no such incidents have been reported with aerosol administration. Reticulocytosis has been reported with aerosol use.

Warnings

Precipitation of the drug in respiratory equipment and consequent accumulation of fluid in the tubing has caused difficulties for patients requiring assisted ventilation. In infants requiring assisted ventilation Virazid should only be used when there is constant monitoring of both patients and equipment.

Directions for use during assisted ventilation are given in the SPAG manual which should be read carefully before such administration.

Full prescribing information is available upon request.


▼ Special reporting to the CSM required.

Basic NHS Price: 1 x 6g vial £195.

Product Licence Number : 4657/0004

Product Licence Holder : Viratek Inc. USA
Supplied By : Britannia Pharmaceuticals Ltd
Forum House
41-51 Brighton Road
Redhill, Surrey,
RH1 6YS

**IVAC IV Therapy.
It's like having
X-ray eyes**



Unfortunately, the most common causes of IV complications are not always visible to the naked eye, so you have to trust the IV instrument to help you.

Imagine a blocked IV, the patient stops receiving critical medication, or imagine a vesicant solution, such as potassium which is being infused interstitially due to an infiltration.

You need to know about it fast.
Fast enough to take corrective action before





the patient is at risk.

IVAC instruments actually 'monitor' the IV site while they deliver the medication, to let you know what's happening fast and keep you better informed.

Fast warning of IV problems, consistent, accurate delivery and simple operation all helps take the risk out of IV therapy.

And unless you've got X-ray eyes IV therapy can really be like working in the dark.

Call us – Telephone (0256) 474455



**NO ONE
KNOWS MORE
ABOUT
IV CONTROL**

A Lilly Medical Instrument Systems Company

IVAC

*Mark owned by IVAC Corporation

IVAC, INTEC 2 BUILDINGS, WADE ROAD, BASINGSTOKE, HANTS RG24 0NE.

"It's elemental my dear Watson"

new



For the effective nutritional care of infants with malabsorption problems, the answer may be elemental.

Pepti-Junior is a balanced elemental feed, which is easily digested and well absorbed.¹⁻⁴ It has been specially developed for infants and young children with digestive or malabsorption problems and/or severe food intolerances.

Pepti-Junior is well tolerated,¹ with a highly palatable taste.

The formulation comprises hydrolysed whey protein, glucose syrup, MCT oil, maize oil, minerals and vitamins.

Osmolality is low at 210 mosmol/kg H₂O.

PEPTI- JUNIOR

Pepti-Junior is ACBS prescribable, and the latest addition to the extensive Cow & Gate range of Specialised Formula Foods.

**Cow
& Gate**

The balanced elemental formula for infant malabsorption

References 1. Taylor CJ, Jenkins P, Manning D *Clinical Nutrition*, 1988; **7**: 183-190. 2. Keohane PP, Grimble GK, Brown B et al. *Gut*, 1985; **26**: 907-913. 3. Silk DBA et al. *JPEN*, 1980; **4**: 548-553. 4. Silk DBA et al *Gut* 1979; **20**: 291-299. Breast milk is the best milk for babies. PEPTI-JUNIOR has been prepared for infants with impaired gastrointestinal function and/or severe food intolerances. PEPTI-JUNIOR should only be used under strict medical supervision. For further information contact Cow & Gate, Medical Department, Trowbridge, Wiltshire BA14 8YX. (0225 768381).

MONATS KINDER SCHRIFT HEILKUNDE

138. Band Heft 8
August 1990

Organ der
Deutschen Gesellschaft
für Kinderheilkunde

Thema des Monats

Morphologische und funktionelle Diagnostik mittels Sonographie

Editorial 415

G. Jorch, H. Rabe,
G. Germani, N. Moeremans
Kreislaufüberwachung bei
sehr kleinen Frühgeborenen
durch Doppler-Sonographie 416

B. Limberg
Kolonsonographie — eine
neue Methode zur Diagnostik
von Morbus Crohn
und Colitis ulcerosa 422

Pädiatrie aktuell

Thrombozytose bei Kindern

Diätetische Behandlung von
Jugendlichen mit Phenylketonurie (PKU) mit Valin,
Isoleuzin und Leuzin

Verschlechtert die
Kolonisation der Lunge mit
Pseudomonas aeruginosa
den klinischen Verlauf bei
Patienten mit Cystischer
Fibrose (CF)? 427

Was hat das Kind?

Trainingsprogramm für die
Weiterbildung zum Kinderarzt 428

Klinik und Forschung

Ch. Tschauner, W. Klapsch,
R. Graf

Das sonographische Neugeborenen-Screening des
Hüftgelenkes — Luxus oder
Notwendigkeit? 429

J. Reiß, M. Schlösser,
M. Wagner, U. Lenz,
M. Krawczak, G. Ammann,
S. Klösser, B. Böwing
Direkte Gendiagnostik bei
zystischer Fibrose 434

U. Wick, P. Kühnl, W. Engel
Analyse der α_1 -Antitrypsin-
Defizienz durch DNA-
Methoden 438

F. K. Tegtmeier, J. Otte,
C. Horn

Bestimmung des C-reaktiven
Proteins (CRP) aus Kapillarblut — ein Vergleich mit
der CRP-Konzentration in
venösem Serum 443

Der interessante Fall

B. Maak, M. Meyer, H. Dietze
Erworbene Dysfibrinogenämie bei einem Kind
im Verlauf einer Lebererkrankung 446

J. Schaper, T. König
Tuberöse Sklerose —
seltene pulmonale Manifestation 451

N. Gordjani, V. Kretschmer,
U. Töllner, C. Rieger
Foudroyant verlaufende
Autoimmunhämolyse vom
Kältetyp mit ausgeprägter
Vermehrung von monothermischen Kälteagglutininen: Erfolgreiche Therapie
mit Membranplasmapherese 454

Wußten Sie schon?

Neues aus Therapie
und Prophylaxe

R. Cremer, K. Kellermann
Konzept, Untersuchungsprogramm und Ergebnisse
der ambulanten Betreuung
von Kindern mit Meningomyelozelen (Spina bifida) 457

Was hat das Kind?

Auflösung und Kommentar
des Trainingsprogramms 470

Aus Gesellschaften und
Berufsverband 461

Neue Bücher 471

Tagesgeschichte,
Personalia 471

Tagungskalender 472

Abstracts der 86. Jahrestagung der Deutschen
Gesellschaft für Kinderheilkunde, 16.—19. September
1990 in Köln 473



Springer-Verlag
Berlin Heidelberg New York
London Paris Tokyo
Hong Kong Barcelona

Annual subscription: DM 298,- plus postage

European Journal of

Pediatrics

Incorporating

Acta Paediatrica Belgica

and

Helvetica Paediatrica Acta

Volume 149 No. 12 1990

The pioneers of pediatric medicine 813

Review

Childhood Lyme borreliosis in Europe

H.-I. Huppertz 814

Annotation

Thoughts of a reviewer
H. J. Schmidt 822

Endocrinology

Growth and endocrine disorder in optic glioma

R. Brauner, F. Malandry,
R. Rappaport, J. M. Zucker,
C. Kalifa, A. Pierre-Kahn,
P. Bataini, J. L. Dufier 825

Gastroenterology/ Hepatology

Cellular cytotoxicity against autologous hepatocytes in children with different forms of chronic hepatitis B

K. M. Keller, T. Poralla,
H. P. Dienes, S. Wirth,
W. Baumann 829

Prevalence and diagnostic significance of gliadin antibodies in children with Down syndrome
W. Storm 833

Growth and development

Neurological outcome in high risk weight appropriate for gestational age preterm children at early school age
R. H. Largo, L. Molinari,
S. Kundu, U. Hunziker, G. Duc 835

Intellectual outcome, speech and school performance in high risk preterm children with birth weight appropriate for gestational age
R. H. Largo, L. Molinari,
S. Kundu, A. Lipp, G. Duc 845

Neonatology

Pulse oximetry used for documenting oxygen saturation and right-to-left shunting immediately after birth

P. Meier-Stauss, H. U. Bucher,
R. Hürlimann, V. König,
R. Huch 851

Neuropediatrics

Cardiomyopathy and multicore myopathy with accumulation of intermediate filaments

E. Bertini, C. Bosman,
M. Bevilacqua, E. Ricci,
G. M. Gagliardi, F. Parisi,
S. Servidei, C. Dionisi-Vici,
L. Ballerini 856

Oncology

Fluctuation in the concentrations of vanillylmandelic acid and homovanillic acid in mass screening for neuroblastoma

M. Nishi, H. Miyake, T. Takeda,
K. Yamashiro, N. Takasugi,
J. Hanai, T. Kawai 859

Lung volumes following resection of pulmonary metastases in paediatric patients – a retrospective study

K. P. Paul, H. Toomes,
I. Vogt-Moykopf 862

Letter to the editors

Pelvic lipomatosis in the Proteus syndrome: a further diagnostic sign

G. Beluffi, G. Di Guilio, P. Fiori 866

Contents of volume 149

Index of key words

Indexed in *Current Contents*



Springer International

Subscription information

Volume 149 (12 issues) will appear in 1990. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: approx. US \$ 868.00 (single issue price approx. \$ 87.00), including carriage charges. Subscriptions are entered with prepayment only.

Orders should be addressed to:

Springer-Verlag New York Inc.
Service Center Secaucus
44 Hartz Way
Secaucus, NJ 07094, USA
Tel. (201) 348-4033
Telex 023125994
FAX (201) 348-4505


All other countries. Annual subscription rate: DM 1532.00 plus carriage charges; Federal Republic of Germany: DM 20.54 incl. value added tax; all other countries: DM 39.00 ex-

cept for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 103.80, India DM 75.00, Australia/New Zealand DM 119.40. Airmail delivery to all other countries is available upon request. Volume price: DM 1532.00, single issue price: DM 153.20 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag
Heidelberger Platz 3, D-1000 Berlin 33
Tel. (0)30/8207-0, Telex 183319
FAX (0)30/8214091

..... POSTAL CODE

Genetics is a subject fundamental to medicine, but rapid advances in recent years may make the subject complex and confusing to clinicians and paramedical staff outside the specialty. Nevertheless, the demand for genetic investigation and counselling is increasing, and these services need to be offered by clinicians other than clinical geneticists. In the *ABC of Clinical Genetics* Helen Kingston, consultant clinical geneticist at St. Mary's Hospital, Manchester, reviews basic concepts of inheritance in mendelian, chromosomal, and multifactorial disorders; outlines the investigation and management of genetic conditions; and illustrates the application of recombinant DNA technology to clinical practice. Implications of genetic diseases for relatives are also considered, together with the ethical and human dilemmas that face doctors and patients and their families.



ORDER FORM

BRITISH MEDICAL JOURNAL
PO Box 295,
London WC1H 9TE,
or any leading bookseller

Please send me

☐ ABC OF CLINICAL GENETICS
and the following BMJ books:

.....
.....

NAME

ADDRESS

POSTCODE

I enclose BMA Membership No.

Please make cheques payable to British Medical Journal
or debit my credit card (please tick box)



☐ Visa ☐ American Express ☐ Mastercard

Card No.


Card expiry date

Signature

☐ Please send me a book catalogue



Inland £10.95; Abroad £13.00
BMA Members:
Inland £9.95; Abroad £12.00
including postage, by air abroad



All the benefits of
the NovoPen® system
are in the bag

PenMix 30/70 is the first pre-mixed insulin for use
in the NovoPen system.

At last diabetic patients can benefit from a simple bd
insulin regimen with the added convenience of NovoPen II.

INTEGRATED DIABETIC CARE

Abbreviated Prescribing Information PenMix® 30/70 100iu/ml (Biphasic Isophane Insulin Injection 30/70, Human Insulin (pvr)). **Indications:** The treatment of insulin-requiring diabetics. **Dosage and Administration:** The dosage is determined by the Physician according to the needs of the patient. Given by subcutaneous injection and intended for use in the NovoPen and NovoPen II injection devices only. (See instructions for use of devices.) Resuspend before use by agitating up and down. **Contra-indications:** Hypoglycaemia. **Precautions:** Injections of PenMix 30/70 should be followed by a meal within 30 minutes of administration. A dosage reduction may be required on transfer from bovine or mixed species insulin. Reduction of early warning symptoms for hypoglycaemia reported by a few patients on transfer from animal source to human insulin. Beta blockers, MAOI's and alcohol may enhance hypoglycaemic effect of insulin. Corticosteroids, thyroid hormones, oral contraceptives may increase insulin requirements. **Use in Pregnancy:** Insulin



PENMIX® 30/70
Human pre-mixed neutral and isophane insulin (pyr)

requirements usually fall during first trimester and increase during second and third trimester. **Side-effects:** Lipodystrophy insulin resistance and hypersensitivity are rarely reported with human insulin. **Product Licence Number and Basic NHS Price:** PL 4668 0020. 5x1.5ml cartridges £8.10. **Product Licence Holder:** Novo Nordisk A/S, Novo Alle, DK-2880 Bagsvaerd, Denmark. **Sole Distributor:** Farillon Limited, Ashton Road, Harold Hill, Romford, Essex RM3 8UE. **Further Information is available on request from:** Novo Nordisk Pharmaceuticals Ltd, Novo Nordisk House, Broadfield Park, Brighton Road, Pease Pottage, Crawley, West Sussex RH11 9RT. Tel: 0293 613555. Fax: 0293 613535.
*Registered Trade Mark of Novo Nordisk A/S

April 1990
Leading the way in diabetic care
FOR FREE NOVOPEN II SUPPLIES DIAL 100 FREEPHONE NOVO NORDISK INSULIN.

Novo Nordisk

